Forward P/S Multiple: Inspira Technologies Oxy B.H.N. Ltd. (IINN)

Is it worth investing in Inspira Technologies Oxy (IINN), given the dependence on FDA approvals and R&D costs? This chart on GURU.Markets reflects the forward P/S ratio, with a current value of 56.30, confirming the stability of ventilator assembly despite partial electronics outsourcing. This will result in profit growth driven by the sale of consumables for blood oxygenation systems.
Summary analytical data breakdowns for Inspira Technologies (IINN)

Inspira Technologies Oxy's monopoly on molecular blood saturation and strict FDA control determine the high value of future cash flows. The ratio of current market capitalization to projected sales allows for an assessment of the premium paid for the technological barrier, while an analysis of forward capitalization to revenue helps identify asset overheating in time to avoid buying at the peak of market optimism.